Skip to main content
Clinical Trials/NCT01576757
NCT01576757
Withdrawn
Not Applicable

Harvest, Isolation and Culture of Cardiac Stem Cells From Endomyocardial Biopsies

University of Louisville1 site in 1 countryFebruary 2011
ConditionsHeart Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
University of Louisville
Locations
1
Primary Endpoint
Determine the efficacy of using endomyocardial biopsy samples to isolate and expand cardiac stem cell cultures.
Status
Withdrawn
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to determine whether the harvest, isolation and culture of cardiac stem cells from endomyocardial biopsies is feasible.

Detailed Description

Heart failure is a devastating condition affecting nearly 6 million patients in the United States alone. Ischemic cardiomyopathy, or pump failure secondary to previous heart attack, is considered by many to be the leading cause of heart failure. Stem cell therapy, or regeneration of the lost myocardium, is an intervention that has the potential for reversing the detrimental effects of this disease. Recently published evidence has shown preliminary results indicating the safety and feasibility of utilizing cardiac stem cells for the treatment of ischemic cardiomyopathy. The ability to use a commonly practiced method, such as endomyocardial biopsy, to isolate and expand stem cell cultures could, potentially, make this therapy widely available. The results of this study will be important for the design of future clinical trials.

Registry
clinicaltrials.gov
Start Date
February 2011
End Date
April 2012
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Roberto Bolli

Endowed Chair Professor

University of Louisville

Eligibility Criteria

Inclusion Criteria

  • Any heart failure patient scheduled for RHC without contraindication for biopsy.
  • Any patient undergoing biopsy for diagnostic purposes may also be included in the study.

Exclusion Criteria

  • Severe comorbidities (AST, ALT, serum creatinine \> 3 times the upper limit of normal).
  • Pregnancy or women of childbearing potential.
  • Anticoagulation which cannot be stopped for 5-7 days.
  • Hepatitis B, C or HIV.
  • Inability to give informed consent.

Outcomes

Primary Outcomes

Determine the efficacy of using endomyocardial biopsy samples to isolate and expand cardiac stem cell cultures.

Time Frame: 6 weeks

Study Sites (1)

Loading locations...

Similar Trials